Companies ›Healthcare ›CTNM

CTNM — Nasdaq Pharmaceuticals

Contineum Therapeutics, Inc.

$15,93

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

595,8M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-12,4 %

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$15,75

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory and fibrotic diseases, currently generating no product revenue and funding operations through equity capital markets.

Business. Contineum Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory and fibrotic diseases, currently generating no product revenue and funding operations through equity capital markets.

Classification93 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY8 analysts

7 buy1 hold0 sell

Avg 12m price target22,86

Analyst recommendations

8 analysts · consensus Buy

Buy7

Hold1

Sell0

12-month price target

22,86

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

8 analysts · indicative

Ownership→

JANUS HENDERSON GROUP PLC

largest disclosed fund holder

Profitability→

-12,4 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CTNM.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CTNM. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Classification93 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

Contineum Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 37.17, reflecting substantial liquidity relative to liabilities. Total assets stand at $250.4 million, with total equity of $239.7 million and cash and equivalents of $14.7 million as of Q2 2026. The company trades at a price-to-book ratio of 2.42, implying a market capitalization of $579.4 million against tangible book value. Operating cash flow is negative at -$27.8 million for the period, driven by ongoing research and development expenditures rather than commercial sales.

The company reports significant unprofitability, with a net loss of $29.6 million and an operating loss of $34.3 million in Q2 2026. Return on equity is -12.36% and return on assets is -11.83%, consistent with a pre-revenue clinical-stage biotechnology firm. These metrics reflect the heavy investment in pipeline development without offsetting product revenue. The negative EV/EBITDA of -10.05 further underscores the absence of earnings before interest, taxes, depreciation, and amortization.

Revenue concentration is not applicable as the company has no reported product revenue. The business model relies entirely on the successful clinical development and eventual commercialization of its drug candidates. The company’s activities are focused on research and development, with no disclosed geographic or segment revenue mix to analyze for concentration risk.

Growth trajectory is defined by capital consumption rather than revenue expansion. The company has consistently reported net losses, with a net loss of $29.6 million in the first half of 2026 compared to $32.0 million in the same period of 2025. Cash and equivalents decreased from $75.6 million at the beginning of the period to $14.7 million by the end of Q2 2026, indicating a rapid burn rate. The company has engaged in multiple equity offerings, including an IPO in 2024, a follow-on offering in late 2025, and at-the-market offerings, to sustain its cash runway.

Risk factors include medium dilution risk due to recent and potential future equity issuances, as indicated by source documents mentioning dilution or offering risk. Liquidity risk is assessed as low given the high current ratio and absence of debt, but the company’s ability to continue operations depends on securing additional capital. Key flags highlight the reliance on external financing to fund development activities.

Recent events include the filing of 8-K reports with material items related to results of operations and financial condition. Analyst estimates show a mean price target of $22.86, with a median of $23.00, and a mean recommendation of 1.62, indicating strong buy sentiment from four analysts and buy sentiment from three others. The company continues to advance its clinical trials, with forward-looking statements addressing the likelihood of safety and efficacy demonstrations for its drug candidates.

Key takeaways

Debt-free balance sheet with a current ratio of 37.17 provides strong short-term liquidity despite negative cash flows.
Significant net loss of $29.6 million in Q2 2026 reflects pre-revenue status and heavy R&D investment.
Rapid cash burn reduced cash and equivalents from $75.6 million to $14.7 million in the first half of 2026.
Medium dilution risk exists due to recent equity offerings and potential need for additional capital.
Strong analyst support with a mean recommendation of 1.62 and mean price target of $22.86.
No product revenue; value is entirely dependent on clinical trial outcomes and future commercialization.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-06-30

Q1 2026 · Quarter highlights

Operating income -$34.3M.

Revenue—

Operating income-$34.3M

Net income-$29.6M

Free cash flow-$28.1M

EPS—

Operating cash flow-$27.8M

Financials

Income statement

Revenue—

Gross profit—

Operating income-$34.3M

Net income-$29.6M

Balance sheet

Total assets$250.4M

Total liabilities$10.7M

Total equity$239.7M

Cash & equivalents$14.7M

Long-term debt—

Cash flow

Operating cash flow-$27.8M

CapEx$318.0k

Free cash flow-$28.1M

SBC$7.7M

Highlights

▍Operating income -$34.3M

Valuation FY

Market price

$15,93

Market cap

$579.4M

Enterprise valueⓘ

$342.8M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

2.4x

P / Tangible bookⓘ

2.4x

Tangible book

$239.7M

Net cashⓘ

$236.6M

Current ratioⓘ

37.2

Debt / equityⓘ

—

ROAⓘ

-11.8%

ROEⓘ

-12.4%

Cash conversionⓘ

94.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

—

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-1,60

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-08-01 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-1,60
Revenue	—no estimate	—no estimate	6,0M USD
Operating income	—no estimate	—no estimate	-70,8M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution8 analysts

Strong buy4

Buy3

Hold1

Sell0

Strong sell0

12-month price target$22,86 · Median $23,00

Low $16,00High $28,00

Operating income · consensus-70,8M USD

EPS surprise

−35,6 %

reported vs consensus · miss

Revenue surprise

−100,0 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$16,00

Mean$22,86

Median$23,00

High$28,00

Spot$15,93

+43.5 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskLow

Filing-based flags

Source documents mention dilution or offering risk.

Benchmarks vs cohort

ROE-12,4 %Bottom quartile

D/E0,00Above P75

Cash Conv0,94Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 1 216 072 sh19 exercises · 13 grants12 insiders

Stengone Carmine N.Director, CEO and President · Stock Option (right to buy) → Class A Common StockDisposed 2 500 @ $1,01exercise · 2026-08-03
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 25 @ $1,01exercise · 2026-07-09
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 1 015 @ $1,01exercise · 2026-07-08
Stengone Carmine N.Director, CEO and President · Stock Option (right to buy) → Class A Common StockDisposed 2 500 @ $1,01exercise · 2026-07-08
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 4 183 @ $1,01exercise · 2026-07-01
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 28 826 @ $1,01exercise · 2026-06-30
Stengone Carmine N.Director, CEO and President · Stock Option (right to buy) → Class A Common StockDisposed 2 500 @ $1,26exercise · 2026-06-30
Watkins TimCMO & Head of Development · Stock Option (right to buy) → Class A Common StockDisposed 10 833 @ $4,50exercise · 2026-06-30
Stengone Carmine N.Director, CEO and President · Stock Option (right to buy) → Class A Common StockDisposed 7 500 @ $1,01exercise · 2026-06-30
Lyons-Williams LoriDirector · Stock Option (right to buy) → Class A Common StockAcquired 19 000 @ $14,19grant · 2026-06-26
Miralles Gines DiegoDirector · Stock Option (right to buy) → Class A Common StockAcquired 19 000 @ $14,19grant · 2026-06-26
Ware Olivia CDirector · Stock Option (right to buy) → Class A Common StockAcquired 19 000 @ $14,19grant · 2026-06-26
Schimmelpennink Evert B.Director · Stock Option (right to buy) → Class A Common StockAcquired 19 000 @ $14,19grant · 2026-06-26
Ignelzi Troy A.Director · Stock Option (right to buy) → Class A Common StockAcquired 19 000 @ $14,19grant · 2026-06-26
Brady Todd R.Director · Stock Option (right to buy) → Class A Common StockAcquired 19 000 @ $14,19grant · 2026-06-26
Boyce SarahDirector · Stock Option (right to buy) → Class A Common StockAcquired 19 000 @ $14,19grant · 2026-06-26
Watkins TimCMO & Head of Development · Stock Option (right to buy) → Class A Common StockDisposed 3 611 @ $4,50exercise · 2026-03-02
Stengone Carmine N.Director, CEO and President · Stock Option (right to buy) → Class A Common StockDisposed 2 700 @ $1,26exercise · 2026-02-25
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 3 824 @ $1,01exercise · 2026-02-25
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 4 300 @ $1,01exercise · 2026-02-24
Stengone Carmine N.Director, CEO and President · Stock Option (right to buy) → Class A Common StockDisposed 4 400 @ $1,26exercise · 2026-02-24
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 100 @ $1,01exercise · 2026-02-19
Lorrain Daniel S.Chief Scientific Officer · Stock Option (right to buy) → Class A Common StockDisposed 400 @ $1,01exercise · 2026-02-11
Stengone Carmine N.Director, CEO and President · Stock Option (right to buy) → Class A Common StockDisposed 400 @ $1,26exercise · 2026-02-11
Healy John StephenGeneral Counsel and Corp Sec · Stock Option (right to buy) → Class A Common StockAcquired 206 411 @ $14,26grant · 2026-01-30

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Market Cap
market_price * shares_outstanding_diluted
Debt To Equity
(short_term_debt + long_term_debt) / total_equity

Source documents

Contineum Therapeutics, Inc. company facts · 2026-08-01
Contineum Therapeutics, Inc. 10-Q 2026-07-30 · 2026-08-01
Contineum Therapeutics, Inc. 10-Q 2026-05-05 · 2026-08-01
Contineum Therapeutics, Inc. 10-K 2026-03-05 · 2026-08-01
Contineum Therapeutics, Inc. 10-Q 2025-10-30 · 2026-08-01
8-K (sec_8k_material) on CTNM · 2026-08-01
Contineum Therapeutics Inc Market data — analyst estimates · 2026-08-01
Contineum Therapeutics Inc Market data — ESG · 2026-08-01

Ownership & reference

Top holders

JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,02 %$36M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$24M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$11M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$3M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$4M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$4M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$15M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$7M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 30 sellsnet -$1,8M3 insiders · last 365d

Stengone Carmine N.Director, CEO and President · Class A Common StockOther 2 500 @ $1,01$3K · 2026-08-03
Stengone Carmine N.Director, CEO and President · Class A Common StockSold 2 500 @ $16,01$40K · 2026-08-03
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockOther 25 @ $1,01$25 · 2026-07-09
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 25 @ $16,00$400 · 2026-07-09
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 1 015 @ $16,00$16K · 2026-07-08
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockOther 1 015 @ $1,01$1K · 2026-07-08
Stengone Carmine N.Director, CEO and President · Class A Common StockOther 2 500 @ $1,01$3K · 2026-07-08
Stengone Carmine N.Director, CEO and President · Class A Common StockSold 2 500 @ $16,00$40K · 2026-07-08
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockOther 4 183 @ $1,01$4K · 2026-07-01
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 5 852 @ $15,67$92K · 2026-07-01
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 2 501 @ $16,24$41K · 2026-07-01
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 28 826 @ $16,04$462K · 2026-06-30
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockOther 28 826 @ $1,01$29K · 2026-06-30
Stengone Carmine N.Director, CEO and President · Class A Common StockSold 10 000 @ $16,01$160K · 2026-06-30
Watkins TimCMO & Head of Development · Class A Common StockSold 10 833 @ $16,02$174K · 2026-06-30
Stengone Carmine N.Director, CEO and President · Class A Common StockOther 7 500 @ $1,01$8K · 2026-06-30
Stengone Carmine N.Director, CEO and President · Class A Common StockOther 2 500 @ $1,26$3K · 2026-06-30
Watkins TimCMO & Head of Development · Class A Common StockOther 10 833 @ $4,50$49K · 2026-06-30
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 4 170 @ $13,16$55K · 2026-06-01
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 300 @ $13,84$4K · 2026-05-01
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 3 870 @ $13,06$51K · 2026-05-01
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 4 170 @ $13,43$56K · 2026-04-06
Watkins TimCMO & Head of Development · Class A Common StockOther 3 611 @ $4,50$16K · 2026-03-02
Lorrain Daniel S.Chief Scientific Officer · Class A Common StockSold 4 170 @ $15,01$63K · 2026-03-02
Watkins TimCMO & Head of Development · Class A Common StockSold 3 611 @ $15,02$54K · 2026-03-02

Short positioning

2.4Mshares short+14.3% vs prior

7.32days to cover

62.1%short of daily vol

4.7Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CTNMCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskMedium

Liquidity riskLow

Source documents mention dilution or offering risk.

Evidence & claims

From filings & derived data

Current assets (annual): USD 267.92MUnknown
EPS (diluted) (annual): USD-PER-SHARES -2Unknown
Total liabilities (annual): USD 15.65MUnknown
Shareholders' equity (annual): USD 260.99MUnknown
Cash & equivalents (annual): USD 75.6MUnknown
Current liabilities (annual): USD 9.74MUnknown
Operating cash flow (annual): USD -55.31MUnknown
EPS (basic) (annual): USD-PER-SHARES -2Unknown
Operating income (annual): USD -68.06MUnknown
Net income (annual): USD -59.98MUnknown
Total operating expenses (annual): USD 68.06MUnknown
Pre-tax income (annual): USD -60.14MUnknown
Total assets (annual): USD 276.64MUnknown
Capex (annual): USD 231KUnknown
R&D expense (annual): USD 51.52MUnknown
Pre-tax income (annual): USD -42.26MUnknown
Shareholders' equity (annual): USD 198.07MUnknown
Current liabilities (annual): USD 9.97MUnknown
Capex (annual): USD 514KUnknown
Current assets (annual): USD 206.39MUnknown
Operating cash flow (annual): USD -32.84MUnknown
Net income (annual): USD -42.26MUnknown
R&D expense (annual): USD 38.42MUnknown
Total operating expenses (annual): USD 50.89MUnknown

Showing 24 of 29 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-31 04:36 UTCFILINGMaterial 8-K

2026-07-09INSIDERLorrain Daniel S. transacted 25 sh Class A Common Stock — Chief Scientific Officer ~$0k

2026-07-09INSIDERLorrain Daniel S. sold 25 sh Class A Common Stock — Chief Scientific Officer ~$0k

2026-07-09INSIDERLorrain Daniel S. disposed of 25 sh Stock Option (right to buy) — Chief Scientific Officer

2026-07-08INSIDERLorrain Daniel S. sold 1.0k sh Class A Common Stock — Chief Scientific Officer ~$16k

2026-07-08INSIDERLorrain Daniel S. transacted 1.0k sh Class A Common Stock — Chief Scientific Officer ~$1k

2026-07-08INSIDERStengone Carmine N. sold 2.5k sh Class A Common Stock — Director, CEO and President ~$40k

2026-07-08INSIDERStengone Carmine N. transacted 2.5k sh Class A Common Stock — Director, CEO and President ~$3k

2026-07-08INSIDERLorrain Daniel S. disposed of 1.0k sh Stock Option (right to buy) — Chief Scientific Officer

2026-07-08INSIDERStengone Carmine N. disposed of 2.5k sh Stock Option (right to buy) — Director, CEO and President

2026-07-01INSIDERLorrain Daniel S. sold 2.5k sh Class A Common Stock — Chief Scientific Officer ~$41k

2026-07-01INSIDERLorrain Daniel S. transacted 4.2k sh Class A Common Stock — Chief Scientific Officer ~$4k

2026-07-01INSIDERLorrain Daniel S. sold 5.9k sh Class A Common Stock — Chief Scientific Officer ~$92k

2026-07-01INSIDERLorrain Daniel S. disposed of 4.2k sh Stock Option (right to buy) — Chief Scientific Officer

2026-06-30EARNINGSQuarterly results — Q1 2026 Net USD -29.6M

2026-06-30INSIDERLorrain Daniel S. sold 28.8k sh Class A Common Stock — Chief Scientific Officer ~$462k

2026-06-30INSIDERLorrain Daniel S. transacted 28.8k sh Class A Common Stock — Chief Scientific Officer ~$29k

2026-06-30INSIDERStengone Carmine N. transacted 2.5k sh Class A Common Stock — Director, CEO and President ~$3k

2026-06-30INSIDERStengone Carmine N. sold 10.0k sh Class A Common Stock — Director, CEO and President ~$160k

2026-06-30INSIDERStengone Carmine N. transacted 7.5k sh Class A Common Stock — Director, CEO and President ~$8k

2026-06-30INSIDERWatkins Tim sold 10.8k sh Class A Common Stock — CMO & Head of Development ~$174k

2026-06-30INSIDERWatkins Tim transacted 10.8k sh Class A Common Stock — CMO & Head of Development ~$49k

2026-06-30INSIDERLorrain Daniel S. disposed of 28.8k sh Stock Option (right to buy) — Chief Scientific Officer

2026-06-30INSIDERStengone Carmine N. disposed of 7.5k sh Stock Option (right to buy) — Director, CEO and President

2026-06-30INSIDERWatkins Tim disposed of 10.8k sh Stock Option (right to buy) — CMO & Head of Development

2026-06-30INSIDERStengone Carmine N. disposed of 2.5k sh Stock Option (right to buy) — Director, CEO and President

2026-06-26 00:00 UTCINSIDER8 insider transactions — 2026-06 7 derivative

2026-06-26INSIDERLyons-Williams Lori acquired 19.0k sh Stock Option (right to buy) — Director

2026-06-26INSIDERBoyce Sarah acquired 19.0k sh Stock Option (right to buy) — Director

2026-06-26INSIDERBrady Todd R. acquired 19.0k sh Stock Option (right to buy) — Director

2026-06-26INSIDERIgnelzi Troy A. acquired 19.0k sh Stock Option (right to buy) — Director

2026-06-26INSIDERSchimmelpennink Evert B. acquired 19.0k sh Stock Option (right to buy) — Director

2026-06-26INSIDERWare Olivia C acquired 19.0k sh Stock Option (right to buy) — Director

2026-06-26INSIDERMiralles Gines Diego acquired 19.0k sh Stock Option (right to buy) — Director

2026-06-01INSIDERLorrain Daniel S. sold 4.2k sh Class A Common Stock — Chief Scientific Officer ~$55k

2026-05-05FILING10-Q filing →

2026-05-05FILING8-K filing →

2026-05-01 00:00 UTCINSIDER2 insider transactions — 2026-05

2026-05-01INSIDERLorrain Daniel S. sold 300 sh Class A Common Stock — Chief Scientific Officer ~$4k

Showing the 40 most recent of 68 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread